AACR Basic Science of Sarcomas

At this CTOS companion meeting, we presented our work on the dynamic (cell cycle dependent) expression of the Pax3:Foxo1 oncogene in rhabdomyosarcoma, and how re-purposing an adult breast cancer drug might be used to silence Pax3:Foxo1 in order to reverse its effects on chemotherapy resistance (and relapse).      

Share this post
Share on facebook
Facebook
Share on google
Google+
Share on twitter
Twitter
Share on linkedin
LinkedIn
Close Menu